Approach to women who become pregnant while on tenofovir disoproxil fumarate for chronic B hepatitis: A report of two cases

Ergen P., Yilmaz Karadag F.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, cilt.46, sa.5, ss.779-783, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 46 Konu: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/jog.14224
  • Sayfa Sayıları: ss.779-783


Mother-to-child transmission of hepatitis B virus can occur during the intrauterine, antenatal and postnatal periods, with an increased risk of perinatal transmission. Appropriate management of patients who are hepatitis B surface antigen positive during pregnancy can substantially reduce the rates of perinatal transmission. Herein, two pregnant women with chronic hepatitis B are presented; one became pregnant while receiving tenofovir disoproxil fumarate and continued the treatment during pregnancy, the other discontinued tenofovir disoproxil fumarate treatment on her own due to conception, but restarted at 26 weeks of pregnancy. At birth the newborns of both women were vaccinated and immunoglobulin was given, with no perinatal transmission. Whether pregnant women should receive antiviral therapy or immunoprophylaxis still remains controversial. In order to keep the mother's liver stable and to prevent perinatal transmission, it is of paramount importance to manage pregnant women in line with the current information and guidelines.